Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.

@article{Laack2002PretreatmentSL,
  title={Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.},
  author={Eckart Laack and Andreas K{\"o}hler and Christof Kugler and Thorsten Dierlamm and Claudia Knuffmann and Gaby Vohwinkel and Annette Niestroy and Nicolaus Dahlmann and Andrea Peters and Jacques Berger and Walter Fiedler and Dieter Kurt Hossfeld},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2002},
  volume={13 10},
  pages={
          1550-7
        }
}
BACKGROUND Matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) are two proteins involved in angiogenesis. In the present study we investigated the association of pretreatment MMP-9 and VEGF serum levels with clinicopathological parameters and outcome in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS From February 1998 to October 1999, pretreatment serum levels of MMP-9 and VEGF were analysed in 118 patients with enzyme-linked immunoassays. At… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 41 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 46 REFERENCES

Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma

  • H Kimura, K Konsihi, T Nukui
  • J Surg Oncol
  • 2001
1 Excerpt

Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis

  • H Han, JF Silverman, TS Santucci
  • Ann Surg Oncol
  • 2001

Similar Papers

Loading similar papers…